Date: 2011-06-29
Type of information: R&D agreement
Compound:
Company: Sanofi (France) Weill CornellMedical College (USA)
Therapeutic area: Infectious diseases
Type agreement: research - R&D
Action mechanism:
Disease: tuberculosis
Details: Sanofi has entered into a research collaboration with Weill Cornell Medical College to identify new antiinfectives that aim to shorten the course of treatment of tuberculosis (TB) and could provide effective therapies against drug-susceptible and drug-resistant strains of TB. Under the terms of the collaboration, Sanofi will provide 80,000 chemical compounds to Dr. Carl Nathan’s laboratory at Weill Cornell, where the compounds will be screened to assess their ability to inhibit growth of Mycobacterium tuberculosis. Weill Cornell has secured funding for the screening activities conducted by Dr. Nathan’s team from the Bill & Melinda Gates Foundation. Sanofi and Weill Cornell will jointly determine if any compounds screened through the collaboration should be brought forward for optimization and potential development.
Financial terms:
Latest news:
